Get the Stockscreener App
10.00
0.89%
-0.09
After Hours:
10.00
Amneal Pharmaceuticals Inc stock is traded at $10.00, with a volume of 1.51M.
It is down -0.89% in the last 24 hours and up +10.86% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$10.09
Open:
$10.02
24h Volume:
1.51M
Relative Volume:
0.94
Market Cap:
$3.14B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-14.70
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
+3.95%
1M Performance:
+10.86%
6M Performance:
+12.61%
1Y Performance:
+18.06%
1-Day Range:
$9.91
$10.11
1-Week Range:
$9.585
$10.34
52-Week Range:
$6.685
$10.34
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
10.00 | 3.08B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-25 | Initiated | Goldman | Buy |
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Amneal receives FDA approval of treatment for narcoleptic sufferers - ROI-NJ
Ophthalmic Packaging Market Worth USD 23.65 Billion by 2034 | Towards Packaging - GlobeNewswire Inc.
Why Amneal (AMRX) Stock Is Up Today - Yahoo Finance
Amneal wins FDA nod for generic targeting Jazz Pharma’s Xyrem - Seeking Alpha
Amneal Pharmaceuticals Wins US FDA Approval for Generic Version of Narcolepsy Drug Xyrem - MarketScreener
Amneal receives US FDA approval of Sodium Oxybate Oral Solution - MarketScreener
Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution - GlobeNewswire
150,000 Narcolepsy Patients Get New Option: Amneal's FDA-Approved Generic Breaks Single-Maker Market - Stock Titan
Amneal Pharmaceuticals: A Large, Diversified Clinical Portfolio That Keeps Growing (AMRX) - Seeking Alpha
Amneal Pharmaceuticals, Inc. $AMRX Shares Bought by Raymond James Financial Inc. - MarketBeat
AMNEAL PHARMACEUTICALS (NASDAQ:AMRX) Reaches New 1-Year HighWhat's Next? - MarketBeat
34,327 Shares in Amneal Pharmaceuticals, Inc. $AMRX Purchased by Ieq Capital LLC - MarketBeat
Northern Trust Corp Reduces Position in AMNEAL PHARMACEUTICALS, INC. $AMRX - MarketBeat
684,116 Shares in AMNEAL PHARMACEUTICALS, INC. $AMRX Bought by Cubist Systematic Strategies LLC - MarketBeat
Anti-Parkinson's Drugs Global Markets to 2030 with AbbVie, Amneal Pharmaceuticals, Acadia Pharmaceut - PharmiWeb.com
Anti-Parkinson's Drugs Global Markets to 2030 with AbbVie, Amneal Pharmaceuticals, Acadia Pharmaceuticals, Supernus Pharmaceuticals and Teva Pharmaceutical DominatingResearchAndMarkets.com - Business Wire
Amneal Pharmaceuticals stock hits 52-week high at $9.79 - Investing.com
Amneal Pharmaceuticals stock hits 52-week high at $9.79 By Investing.com - Investing.com Australia
Is Amneal Pharmaceuticals Inc. a strong growth stockJuly 2025 Analyst Calls & Community Shared Stock Ideas - beatles.ru
AMNEAL PHARMACEUTICALS, INC. $AMRX Shares Bought by Dark Forest Capital Management LP - MarketBeat
Is Amneal Pharmaceuticals Inc.’s ROE strong enough2025 Analyst Calls & Free Real-Time Volume Trigger Notifications - beatles.ru
Should you wait for a breakout in Amneal Pharmaceuticals Inc.Bear Alert & Fast Moving Stock Trade Plans - Newser
Can machine learning forecast Amneal Pharmaceuticals Inc. recoveryPortfolio Value Summary & Stock Portfolio Risk Management - Newser
Amneal Pharmaceuticals, Inc. $AMRX Shares Bought by Nantahala Capital Management LLC - MarketBeat
FDA Warns Amneal Pharmaceuticals Over Use of Contaminated IV Bags in Sterile Injectable Drug Production - geneonline.com
Amneal gets FDA nod for generic version of Risperdal Consta - MSN
Does Amneal Pharmaceuticals Inc. have pricing powerDollar Strength & Weekly Stock Breakout Alerts - خودرو بانک
Trexquant Investment LP Acquires 167,631 Shares of AMNEAL PHARMACEUTICALS, INC. $AMRX - MarketBeat
Should you avoid Amneal Pharmaceuticals Inc. stock right nowJuly 2025 Action & Low Risk Profit Maximizing Plans - خودرو بانک
Using R and stats models for Amneal Pharmaceuticals Inc. forecastingEarnings Risk Report & Advanced Technical Signal Analysis - Newser
What is the Moat Score of Amneal Pharmaceuticals Inc.2025 Biggest Moves & Reliable Entry Point Alerts - خودرو بانک
Why Amneal Pharmaceuticals Inc. is moving todayGap Down & Smart Money Movement Alerts - Newser
FDA approves Amneal’s generic risperidone for schizophrenia treatment By Investing.com - Investing.com Australia
Is Amneal Pharmaceuticals Inc. showing insider buyingCEO Change & Free Expert Verified Stock Movement Alerts - خودرو بانک
Tools to monitor Amneal Pharmaceuticals Inc. recovery probabilityShort Setup & AI Powered Market Trend Analysis - Newser
Published on: 2025-09-05 05:42:34 - Newser
Regression analysis insights on Amneal Pharmaceuticals Inc. performanceWeekly Market Report & Accurate Intraday Trading Signals - Newser
Hsbc Holdings PLC Has $727,000 Stake in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Can Amneal Pharmaceuticals Inc. rally from current levelsWeekly Trend Report & Intraday High Probability Setup Alerts - Newser
Can technical indicators confirm Amneal Pharmaceuticals Inc.’s reversalMarket Movement Recap & Expert Curated Trade Setup Alerts - Newser
Amneal Pharmaceuticals Receives FDA Approval for Antipsychotic Medicine - AInvest
Amneal receives U.S. FDA approval for risperidone extended-release injectable suspension - MarketScreener
FDA approves Amneal’s generic risperidone for schizophrenia treatment - Investing.com
Amneal Pharmaceuticals Receives FDA Approval for Risperidone Extended-Release Injectable Suspension - Quiver Quantitative
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension - GlobeNewswire
Amneal Pharmaceuticals Receives FDA Approval for Risperidone Extended-Release Injectable Suspension, Expanding Complex Injectables Portfolio - AInvest
$194M Market Opportunity: Amneal Secures Exclusive FDA Approval for Complex Injectable Schizophrenia Drug - Stock Titan
Has Amneal Pharmaceuticals Inc. formed a bullish divergence2025 Trade Ideas & Consistent Growth Equity Picks - Newser
Detecting price anomalies in Amneal Pharmaceuticals Inc. with AIQuarterly Market Review & Fast Gain Stock Trading Tips - Newser
Will Amneal Pharmaceuticals Inc. continue its uptrendVolume Spike & Daily Volume Surge Signals - Newser
Can Amneal Pharmaceuticals Inc. expand into new marketsWeekly Investment Summary & Capital Protection Trading Alerts - خودرو بانک
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):